Ads
related to: drugs used for hemophilia
Search results
Results from the WOW.Com Content Network
Marstacimab, sold under the brand name Hympavzi, is a monoclonal antibody medication used for the treatment of hemophilia A and hemophilia B. [1] [4] [2] It is a tissue factor pathway inhibitor (TFPI) antagonist. [4] It was developed by Pfizer. [5]
Factor VIII is a medication used to treat and prevent bleeding in people with hemophilia A and other causes of low factor VIII. [12] [13] Certain preparations may also be used in those with von Willebrand's disease. [13]
When used as drugs, the International Nonproprietary Names (INNs) end in -mab. The remaining syllables of the INNs, as well as the column Source, are explained in Nomenclature of monoclonal antibodies. Types of monoclonal antibodies with other structures than naturally occurring antibodies.
Hympavzi is the first and only anti-tissue factor pathway inhibitor (anti-TFPI) approved in the U.S. for hemophilia A or B and the first hemophilia medicine approved in the U.S. to be administered via
Efanesoctocog alfa, sold under the brand name Altuviiio, is a medication used for the treatment of hemophilia A (congenital factor VIII deficiency). [1] [4] Efanesoctocog alfa was approved for medical use in the United States in February 2023. [1] [4] [5] [6]
The medication desmopressin may be used in those with mild haemophilia A. [16] Studies of gene therapy are in early human trials. [ 17 ] Haemophilia A affects about 1 in 5,000–10,000, while haemophilia B affects about 1 in 40,000 males at birth.
Ads
related to: drugs used for hemophilia